NCT02537457View on ClinicalTrials.gov

Bioequivalence Study of Rivaroxaban

PHASE1CompletedINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

March 31, 2014

Study Completion Date

April 30, 2014

Conditions

Embolism, Atrial Fibrillation and Venous Thrombosis

Interventions

DRUG

Rivaroxaban (BAY 59-7939)

Rivaroxaban granule15mg for one day

DRUG

Rivaroxaban (Xarelto, BAY 59-7939)

Rivaroxaban tablet15mg for one day

Trial Locations (1)

861-4157

Kumamoto

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY